<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Transl Med</journal-id><journal-id journal-id-type="iso-abbrev">J Transl Med</journal-id><journal-title-group><journal-title>Journal of Translational Medicine</journal-title></journal-title-group><issn pub-type="epub">1479-5876</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29843811</article-id><article-id pub-id-type="pmc">5975654</article-id><article-id pub-id-type="publisher-id">1507</article-id><article-id pub-id-type="doi">10.1186/s12967-018-1507-6</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Liau</surname><given-names>Linda M.</given-names></name><address><email>lliau@mednet.ucla.edu</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ashkan</surname><given-names>Keyoumars</given-names></name><address><email>k.ashkan@nhs.net</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Tran</surname><given-names>David D.</given-names></name><address><email>david.tran@neurosurgery.ufl.edu</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Campian</surname><given-names>Jian L.</given-names></name><address><email>Campian.jian@wustl.edu</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Trusheim</surname><given-names>John E.</given-names></name><address><email>John.trusheim@Mpls-clinic.com</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Cobbs</surname><given-names>Charles S.</given-names></name><address><email>Charles.cobbs@swedish.org</email></address><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Heth</surname><given-names>Jason A.</given-names></name><address><email>jheth@med.umich.edu</email></address><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Salacz</surname><given-names>Michael</given-names></name><address><email>msalacz@kumc.edu</email></address><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Taylor</surname><given-names>Sarah</given-names></name><address><email>SATAYLOR@kumc.edu</email></address><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>D&#x02019;Andre</surname><given-names>Stacy D.</given-names></name><address><email>DandrS1@sutterhealth.org</email></address><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Iwamoto</surname><given-names>Fabio M.</given-names></name><address><email>Fi2146@cumc.columbia.edu</email></address><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Dropcho</surname><given-names>Edward J.</given-names></name><address><email>edropcho@iupui.edu</email></address><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>Moshel</surname><given-names>Yaron A.</given-names></name><address><email>ymoshel@ansdocs.com</email></address><xref ref-type="aff" rid="Aff12">12</xref></contrib><contrib contrib-type="author"><name><surname>Walter</surname><given-names>Kevin A.</given-names></name><address><email>Kevin_Walter@URMC.Rochester.edu</email></address><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name><surname>Pillainayagam</surname><given-names>Clement P.</given-names></name><address><email>Clement_Pillainayagam@rush.edu</email></address><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Aiken</surname><given-names>Robert</given-names></name><address><email>Ra615@cinj.rutgers.edu</email></address><xref ref-type="aff" rid="Aff15">15</xref></contrib><contrib contrib-type="author"><name><surname>Chaudhary</surname><given-names>Rekha</given-names></name><address><email>tripatrr@UCMAIL.UC.EDU</email></address><xref ref-type="aff" rid="Aff16">16</xref></contrib><contrib contrib-type="author"><name><surname>Goldlust</surname><given-names>Samuel A.</given-names></name><address><email>Samuel.Goldlust@hackensackmeridian.org</email></address><xref ref-type="aff" rid="Aff17">17</xref></contrib><contrib contrib-type="author"><name><surname>Bota</surname><given-names>Daniela A.</given-names></name><address><email>dbota@uci.edu</email></address><xref ref-type="aff" rid="Aff18">18</xref></contrib><contrib contrib-type="author"><name><surname>Duic</surname><given-names>Paul</given-names></name><address><email>JDuic@nyuwinthrop.org</email></address><xref ref-type="aff" rid="Aff19">19</xref></contrib><contrib contrib-type="author"><name><surname>Grewal</surname><given-names>Jai</given-names></name><address><email>Jgrewal8@gmail.com</email></address><xref ref-type="aff" rid="Aff59">59</xref></contrib><contrib contrib-type="author"><name><surname>Elinzano</surname><given-names>Heinrich</given-names></name><address><email>helinzano@Lifespan.org</email></address><xref ref-type="aff" rid="Aff20">20</xref></contrib><contrib contrib-type="author"><name><surname>Toms</surname><given-names>Steven A.</given-names></name><address><email>Steven.Toms@lifespan.org</email></address><xref ref-type="aff" rid="Aff20">20</xref></contrib><contrib contrib-type="author"><name><surname>Lillehei</surname><given-names>Kevin O.</given-names></name><address><email>Kevin.Lillehei@ucdenver.edu</email></address><xref ref-type="aff" rid="Aff21">21</xref></contrib><contrib contrib-type="author"><name><surname>Mikkelsen</surname><given-names>Tom</given-names></name><address><email>TMIKKEL1@hfhs.org</email></address><xref ref-type="aff" rid="Aff22">22</xref></contrib><contrib contrib-type="author"><name><surname>Walpert</surname><given-names>Tobias</given-names></name><address><email>TWALBER1@hfhs.org</email></address><xref ref-type="aff" rid="Aff22">22</xref></contrib><contrib contrib-type="author"><name><surname>Abram</surname><given-names>Steven R.</given-names></name><address><email>sabram@howellallen.com</email></address><xref ref-type="aff" rid="Aff23">23</xref></contrib><contrib contrib-type="author"><name><surname>Brenner</surname><given-names>Andrew J.</given-names></name><address><email>brennera@uthscsa.edu</email></address><xref ref-type="aff" rid="Aff24">24</xref></contrib><contrib contrib-type="author"><name><surname>Brem</surname><given-names>Steven</given-names></name><address><email>Steven.Brem@uphs.upenn.edu</email></address><xref ref-type="aff" rid="Aff25">25</xref></contrib><contrib contrib-type="author"><name><surname>Ewend</surname><given-names>Matthew G.</given-names></name><address><email>ewend@unchealth.unc.edu</email></address><xref ref-type="aff" rid="Aff26">26</xref></contrib><contrib contrib-type="author"><name><surname>Khagi</surname><given-names>Simon</given-names></name><address><email>skhagi@med.unc.edu</email></address><xref ref-type="aff" rid="Aff26">26</xref></contrib><contrib contrib-type="author"><name><surname>Portnow</surname><given-names>Jana</given-names></name><address><email>JPortnow@coh.org</email></address><xref ref-type="aff" rid="Aff27">27</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Lyndon J.</given-names></name><address><email>lyndon.kim@jefferson.edu</email></address><xref ref-type="aff" rid="Aff28">28</xref></contrib><contrib contrib-type="author"><name><surname>Loudon</surname><given-names>William G.</given-names></name><address><email>wgloudon@gmail.com</email></address><xref ref-type="aff" rid="Aff29">29</xref></contrib><contrib contrib-type="author"><name><surname>Thompson</surname><given-names>Reid C.</given-names></name><address><email>Reid.thompson@Vanderbilt.Edu</email></address><xref ref-type="aff" rid="Aff30">30</xref></contrib><contrib contrib-type="author"><name><surname>Avigan</surname><given-names>David E.</given-names></name><address><email>davigan@bidmc.harvard.edu</email></address><xref ref-type="aff" rid="Aff31">31</xref></contrib><contrib contrib-type="author"><name><surname>Fink</surname><given-names>Karen L.</given-names></name><address><email>Karen.Fink@BSWHealth.org</email></address><xref ref-type="aff" rid="Aff32">32</xref></contrib><contrib contrib-type="author"><name><surname>Geoffroy</surname><given-names>Francois J.</given-names></name><address><email>FGEOFFROY@illinoiscancercare.com</email></address><xref ref-type="aff" rid="Aff33">33</xref></contrib><contrib contrib-type="author"><name><surname>Lindhorst</surname><given-names>Scott</given-names></name><address><email>lindhors@musc.edu</email></address><xref ref-type="aff" rid="Aff34">34</xref></contrib><contrib contrib-type="author"><name><surname>Lutzky</surname><given-names>Jose</given-names></name><address><email>Jose.Lutzky@msmc.com</email></address><xref ref-type="aff" rid="Aff35">35</xref></contrib><contrib contrib-type="author"><name><surname>Sloan</surname><given-names>Andrew E.</given-names></name><address><email>Andrew.Sloan@UHhospitals.org</email></address><xref ref-type="aff" rid="Aff36">36</xref></contrib><contrib contrib-type="author"><name><surname>Schackert</surname><given-names>Gabriele</given-names></name><address><email>Gabriele.Schackert@uniklinikum-dresden.de</email></address><xref ref-type="aff" rid="Aff37">37</xref></contrib><contrib contrib-type="author"><name><surname>Krex</surname><given-names>Dietmar</given-names></name><address><email>Dietmar.Krex@uniklinikum-dresden.de</email></address><xref ref-type="aff" rid="Aff37">37</xref></contrib><contrib contrib-type="author"><name><surname>Meisel</surname><given-names>Hans-Jorg</given-names></name><address><email>meisel@bergmannstrost.com</email></address><xref ref-type="aff" rid="Aff38">38</xref></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Julian</given-names></name><address><email>jwu3@tuftsmedicalcenter.org</email></address><xref ref-type="aff" rid="Aff39">39</xref></contrib><contrib contrib-type="author"><name><surname>Davis</surname><given-names>Raphael P.</given-names></name><address><email>raphael.davis@stonybrookmedicine.edu</email></address><xref ref-type="aff" rid="Aff40">40</xref></contrib><contrib contrib-type="author"><name><surname>Duma</surname><given-names>Christopher</given-names></name><address><email>cduma@mac.com</email></address><xref ref-type="aff" rid="Aff41">41</xref></contrib><contrib contrib-type="author"><name><surname>Etame</surname><given-names>Arnold B.</given-names></name><address><email>Arnold.Etame@moffitt.org</email></address><xref ref-type="aff" rid="Aff42">42</xref></contrib><contrib contrib-type="author"><name><surname>Mathieu</surname><given-names>David</given-names></name><address><email>David.Mathieu@USherbrooke.ca</email></address><xref ref-type="aff" rid="Aff43">43</xref></contrib><contrib contrib-type="author"><name><surname>Kesari</surname><given-names>Santosh</given-names></name><address><email>KesariS@jwci.org</email></address><xref ref-type="aff" rid="Aff44">44</xref></contrib><contrib contrib-type="author"><name><surname>Piccioni</surname><given-names>David</given-names></name><address><email>dpiccioni@ucsd.edu</email></address><xref ref-type="aff" rid="Aff44">44</xref></contrib><contrib contrib-type="author"><name><surname>Westphal</surname><given-names>Manfred</given-names></name><address><email>westphal@uke.de</email></address><xref ref-type="aff" rid="Aff45">45</xref></contrib><contrib contrib-type="author"><name><surname>Baskin</surname><given-names>David S.</given-names></name><address><email>DBaskin@houstonmethodist.org</email></address><xref ref-type="aff" rid="Aff46">46</xref></contrib><contrib contrib-type="author"><name><surname>New</surname><given-names>Pamela Z.</given-names></name><address><email>pnew@houstonmethodist.org</email></address><xref ref-type="aff" rid="Aff46">46</xref></contrib><contrib contrib-type="author"><name><surname>Lacroix</surname><given-names>Michel</given-names></name><address><email>mlacroix1@geisinger.edu</email></address><xref ref-type="aff" rid="Aff47">47</xref></contrib><contrib contrib-type="author"><name><surname>May</surname><given-names>Sven-Axel</given-names></name><address><email>s-a.may@skc.de</email></address><xref ref-type="aff" rid="Aff48">48</xref></contrib><contrib contrib-type="author"><name><surname>Pluard</surname><given-names>Timothy J.</given-names></name><address><email>tpluard@saint-lukes.org</email></address><xref ref-type="aff" rid="Aff49">49</xref></contrib><contrib contrib-type="author"><name><surname>Tse</surname><given-names>Victor</given-names></name><address><email>Victor.C.Tse@kp.org</email></address><xref ref-type="aff" rid="Aff50">50</xref></contrib><contrib contrib-type="author"><name><surname>Green</surname><given-names>Richard M.</given-names></name><address><email>Richard.M.Green@kp.org</email></address><xref ref-type="aff" rid="Aff51">51</xref></contrib><contrib contrib-type="author"><name><surname>Villano</surname><given-names>John L.</given-names></name><address><email>jlvillano@uky.edu</email></address><xref ref-type="aff" rid="Aff52">52</xref></contrib><contrib contrib-type="author"><name><surname>Pearlman</surname><given-names>Michael</given-names></name><address><email>mpearlman@carepointhc.com</email></address><xref ref-type="aff" rid="Aff53">53</xref></contrib><contrib contrib-type="author"><name><surname>Petrecca</surname><given-names>Kevin</given-names></name><address><email>kevin.petrecca@mcgill.ca</email></address><xref ref-type="aff" rid="Aff54">54</xref></contrib><contrib contrib-type="author"><name><surname>Schulder</surname><given-names>Michael</given-names></name><address><email>mschulder@northwell.edu</email></address><xref ref-type="aff" rid="Aff55">55</xref></contrib><contrib contrib-type="author"><name><surname>Taylor</surname><given-names>Lynne P.</given-names></name><address><email>ltaylor@uw.edu</email></address><xref ref-type="aff" rid="Aff56">56</xref></contrib><contrib contrib-type="author"><name><surname>Maida</surname><given-names>Anthony E.</given-names></name><address><email>amaida@nwbio.com</email></address><xref ref-type="aff" rid="Aff58">58</xref></contrib><contrib contrib-type="author"><name><surname>Prins</surname><given-names>Robert M.</given-names></name><address><email>rprins@mednet.ucla.edu</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Cloughesy</surname><given-names>Timothy F.</given-names></name><address><email>tcloughesy@mednet.ucla.edu</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Mulholland</surname><given-names>Paul</given-names></name><address><email>paul.mulholland@nhs.net</email></address><xref ref-type="aff" rid="Aff57">57</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8831-8456</contrib-id><name><surname>Bosch</surname><given-names>Marnix L.</given-names></name><address><email>marnix@nwbio.com</email></address><xref ref-type="aff" rid="Aff58">58</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9632 6718</institution-id><institution-id institution-id-type="GRID">grid.19006.3e</institution-id><institution>University of California Los Angeles (UCLA) David Geffen School of Medicine &#x00026; Jonsson Comprehensive Cancer Center, </institution></institution-wrap>Los Angeles, CA USA </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2322 6764</institution-id><institution-id institution-id-type="GRID">grid.13097.3c</institution-id><institution>King&#x02019;s College London School of Medical Education, </institution></institution-wrap>London, UK </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 8091</institution-id><institution-id institution-id-type="GRID">grid.15276.37</institution-id><institution>University of Florida, </institution></institution-wrap>Gainesville, FL USA </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2355 7002</institution-id><institution-id institution-id-type="GRID">grid.4367.6</institution-id><institution>Washington University, </institution></institution-wrap>St. Louis, MO USA </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 8795 611X</institution-id><institution-id institution-id-type="GRID">grid.413195.b</institution-id><institution>Abbott Northwestern Hospital, </institution></institution-wrap>Minneapolis, MN USA </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0463 5388</institution-id><institution-id institution-id-type="GRID">grid.281044.b</institution-id><institution>Swedish Medical Center, </institution><institution>Swedish Neuroscience Institute, </institution></institution-wrap>Seattle, WA USA </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ISNI">0000000086837370</institution-id><institution-id institution-id-type="GRID">grid.214458.e</institution-id><institution>University of Michigan Medical School, </institution></institution-wrap>Ann Arbor, MI USA </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0408 2680</institution-id><institution-id institution-id-type="GRID">grid.468219.0</institution-id><institution>University of Kansas Cancer Center, </institution></institution-wrap>Kansas City, KS USA </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="GRID">grid.430769.f</institution-id><institution>Sutter Institute for Medical Research, </institution></institution-wrap>Sacramento, CA USA </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2285 2675</institution-id><institution-id institution-id-type="GRID">grid.239585.0</institution-id><institution>Columbia University Medical Center, </institution></institution-wrap>New York, NY USA </aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2287 3919</institution-id><institution-id institution-id-type="GRID">grid.257413.6</institution-id><institution>Indiana University Simon Cancer Center, </institution></institution-wrap>Indianapolis, IN USA </aff><aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 8945 8587</institution-id><institution-id institution-id-type="GRID">grid.417328.b</institution-id><institution>Overlook Medical Center, </institution></institution-wrap>Summit, NJ USA </aff><aff id="Aff13"><label>13</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 9166</institution-id><institution-id institution-id-type="GRID">grid.412750.5</institution-id><institution>University of Rochester Medical Center, </institution></institution-wrap>Rochester, NY USA </aff><aff id="Aff14"><label>14</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0705 3621</institution-id><institution-id institution-id-type="GRID">grid.240684.c</institution-id><institution>Rush University Medical Center, </institution></institution-wrap>Rochester, USA </aff><aff id="Aff15"><label>15</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 8796</institution-id><institution-id institution-id-type="GRID">grid.430387.b</institution-id><institution>Rutgers Cancer Institute, </institution></institution-wrap>New Brunswick, NJ USA </aff><aff id="Aff16"><label>16</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9881 9161</institution-id><institution-id institution-id-type="GRID">grid.413561.4</institution-id><institution>University of Cincinnati Medical Center, </institution></institution-wrap>Cincinnati, OH USA </aff><aff id="Aff17"><label>17</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0407 6328</institution-id><institution-id institution-id-type="GRID">grid.239835.6</institution-id><institution>Hackensack University Medical Center, </institution></institution-wrap>Hackensack, NJ USA </aff><aff id="Aff18"><label>18</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0434 883X</institution-id><institution-id institution-id-type="GRID">grid.417319.9</institution-id><institution>UC Irvine Medical Center, </institution></institution-wrap>Irvine, CA USA </aff><aff id="Aff19"><label>19</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0228 085X</institution-id><institution-id institution-id-type="GRID">grid.281603.e</institution-id><institution>Winthrop-University Hospital, </institution></institution-wrap>Mineola, NY USA </aff><aff id="Aff20"><label>20</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0557 9478</institution-id><institution-id institution-id-type="GRID">grid.240588.3</institution-id><institution>Rhode Island Hospital, </institution></institution-wrap>Providence, RI USA </aff><aff id="Aff21"><label>21</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9908 7089</institution-id><institution-id institution-id-type="GRID">grid.413085.b</institution-id><institution>University of Colorado Hospital, </institution></institution-wrap>Aurora, CO USA </aff><aff id="Aff22"><label>22</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 8523 7701</institution-id><institution-id institution-id-type="GRID">grid.239864.2</institution-id><institution>Henry Ford Health System, </institution></institution-wrap>Detroit, MI USA </aff><aff id="Aff23"><label>23</label>St. Thomas Research Institute, Nashville, TN USA </aff><aff id="Aff24"><label>24</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0629 5880</institution-id><institution-id institution-id-type="GRID">grid.267309.9</institution-id><institution>University of Texas Health Science Center, </institution></institution-wrap>San Antonio, TX USA </aff><aff id="Aff25"><label>25</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 8972</institution-id><institution-id institution-id-type="GRID">grid.25879.31</institution-id><institution>University of Pennsylvania Perelman School of Medicine, </institution></institution-wrap>Philadelphia, PA USA </aff><aff id="Aff26"><label>26</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 1034 1720</institution-id><institution-id institution-id-type="GRID">grid.410711.2</institution-id><institution>University of North Carolina, </institution></institution-wrap>Chapel Hill, NC USA </aff><aff id="Aff27"><label>27</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0421 8357</institution-id><institution-id institution-id-type="GRID">grid.410425.6</institution-id><institution>City of Hope National Medical Center, </institution></institution-wrap>Duarte, CA USA </aff><aff id="Aff28"><label>28</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2166 5843</institution-id><institution-id institution-id-type="GRID">grid.265008.9</institution-id><institution>Thomas Jefferson University, </institution></institution-wrap>Philadelphia, PA USA </aff><aff id="Aff29"><label>29</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0450 7802</institution-id><institution-id institution-id-type="GRID">grid.416692.e</institution-id><institution>St. Joseph Hospital, </institution></institution-wrap>Newport Beach, CA USA </aff><aff id="Aff30"><label>30</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2264 7217</institution-id><institution-id institution-id-type="GRID">grid.152326.1</institution-id><institution>Vanderbilt University, </institution></institution-wrap>Nashville, TN USA </aff><aff id="Aff31"><label>31</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9011 8547</institution-id><institution-id institution-id-type="GRID">grid.239395.7</institution-id><institution>Beth Israel Deaconess Medical Center, </institution></institution-wrap>Boston, MA USA </aff><aff id="Aff32"><label>32</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2167 9807</institution-id><institution-id institution-id-type="GRID">grid.411588.1</institution-id><institution>Baylor University Medical Center, </institution></institution-wrap>Dallas, TX USA </aff><aff id="Aff33"><label>33</label><institution-wrap><institution-id institution-id-type="GRID">grid.428927.2</institution-id><institution>Illinois CancerCare, </institution></institution-wrap>Peoria, IL USA </aff><aff id="Aff34"><label>34</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2189 3475</institution-id><institution-id institution-id-type="GRID">grid.259828.c</institution-id><institution>Medical University of South Carolina, </institution></institution-wrap>Charleston, SC USA </aff><aff id="Aff35"><label>35</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0430 4458</institution-id><institution-id institution-id-type="GRID">grid.410396.9</institution-id><institution>Mount Sinai Comprehensive Cancer Center, </institution></institution-wrap>Miami, FL USA </aff><aff id="Aff36"><label>36</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9149 4843</institution-id><institution-id institution-id-type="GRID">grid.443867.a</institution-id><institution>University Hospitals Case Medical Center, </institution></institution-wrap>Cleveland, OH USA </aff><aff id="Aff37"><label>37</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 1091 2917</institution-id><institution-id institution-id-type="GRID">grid.412282.f</institution-id><institution>University Hospital Carl-Gustav-Carus of Technical University, </institution></institution-wrap>Dresden, Germany </aff><aff id="Aff38"><label>38</label>BG-Klinikum Bergmannstrost, Halle, Germany </aff><aff id="Aff39"><label>39</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 8934 4045</institution-id><institution-id institution-id-type="GRID">grid.67033.31</institution-id><institution>Tufts University School of Medicine, </institution></institution-wrap>Boston, MA USA </aff><aff id="Aff40"><label>40</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2216 9681</institution-id><institution-id institution-id-type="GRID">grid.36425.36</institution-id><institution>Stony Brook University, </institution></institution-wrap>Stony Brook, NY USA </aff><aff id="Aff41"><label>41</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9755 6590</institution-id><institution-id institution-id-type="GRID">grid.414587.b</institution-id><institution>Hoag Cancer Center, </institution></institution-wrap>Newport Beach, CA USA </aff><aff id="Aff42"><label>42</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9891 5233</institution-id><institution-id institution-id-type="GRID">grid.468198.a</institution-id><institution>H. Lee Moffit Cancer Center and Research Institute, </institution></institution-wrap>Tampa, FL USA </aff><aff id="Aff43"><label>43</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9064 6198</institution-id><institution-id institution-id-type="GRID">grid.86715.3d</institution-id><institution>CHUS-Hopital Fleurimont, Sherbrooke University, </institution></institution-wrap>Sherbrooke, QC Canada </aff><aff id="Aff44"><label>44</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2107 4242</institution-id><institution-id institution-id-type="GRID">grid.266100.3</institution-id><institution>UCSD Health System, UC San Diego, </institution></institution-wrap>San Diego, CA USA </aff><aff id="Aff45"><label>45</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2180 3484</institution-id><institution-id institution-id-type="GRID">grid.13648.38</institution-id><institution>Neurochirurgische Klinik University Clinic Hamburg-Eppendorf, </institution></institution-wrap>Hamburg, Germany </aff><aff id="Aff46"><label>46</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0445 0041</institution-id><institution-id institution-id-type="GRID">grid.63368.38</institution-id><institution>Houston Methodist, </institution></institution-wrap>Houston, TX USA </aff><aff id="Aff47"><label>47</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0394 1447</institution-id><institution-id institution-id-type="GRID">grid.280776.c</institution-id><institution>Geisinger Health System, </institution></institution-wrap>Danville, PA USA </aff><aff id="Aff48"><label>48</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0389 4214</institution-id><institution-id institution-id-type="GRID">grid.459629.5</institution-id><institution>Klinikum Chemnitz GGMBH, </institution></institution-wrap>Chemnitz, Germany </aff><aff id="Aff49"><label>49</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0383 1037</institution-id><institution-id institution-id-type="GRID">grid.419820.6</institution-id><institution>Saint Luke&#x02019;s Cancer Institute, </institution></institution-wrap>Kansas City, MO USA </aff><aff id="Aff50"><label>50</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9957 7758</institution-id><institution-id institution-id-type="GRID">grid.280062.e</institution-id><institution>Kaiser Permanente Northern California, </institution></institution-wrap>Redwood City, CA USA </aff><aff id="Aff51"><label>51</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9957 7758</institution-id><institution-id institution-id-type="GRID">grid.280062.e</institution-id><institution>Kaiser Permanente Southern California, </institution></institution-wrap>Los Angeles, CA USA </aff><aff id="Aff52"><label>52</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 8438</institution-id><institution-id institution-id-type="GRID">grid.266539.d</institution-id><institution>University of Kentucky College of Medicine, </institution></institution-wrap>Lexington, KY USA </aff><aff id="Aff53"><label>53</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0480 7493</institution-id><institution-id institution-id-type="GRID">grid.433646.0</institution-id><institution>Colorado Neurological Institute, </institution></institution-wrap>Englewood, CO USA </aff><aff id="Aff54"><label>54</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 8649</institution-id><institution-id institution-id-type="GRID">grid.14709.3b</institution-id><institution>Montreal Neurological Institute and Hospital, McGill University, </institution></institution-wrap>Montreal, Canada </aff><aff id="Aff55"><label>55</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 8753</institution-id><institution-id institution-id-type="GRID">grid.137628.9</institution-id><institution>Northwell Hofstra School of Medicine, </institution></institution-wrap>Lake Success, NY USA </aff><aff id="Aff56"><label>56</label><institution-wrap><institution-id institution-id-type="ISNI">0000000122986657</institution-id><institution-id institution-id-type="GRID">grid.34477.33</institution-id><institution>Department of Neurology, Alvord Brain Tumor Center, </institution><institution>University of Washington, </institution></institution-wrap>Seattle, WA USA </aff><aff id="Aff57"><label>57</label><institution-wrap><institution-id institution-id-type="ISNI">0000000121901201</institution-id><institution-id institution-id-type="GRID">grid.83440.3b</institution-id><institution>University College Hospitals, </institution></institution-wrap>London, UK </aff><aff id="Aff58"><label>58</label><institution-wrap><institution-id institution-id-type="GRID">grid.436541.1</institution-id><institution>Northwest Biotherapeutics Inc., </institution></institution-wrap>Bethesda, MD USA </aff><aff id="Aff59"><label>59</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 8753</institution-id><institution-id institution-id-type="GRID">grid.137628.9</institution-id><institution>NYU Winthrop Hospital, </institution></institution-wrap>Mineola, NY USA </aff></contrib-group><pub-date pub-type="epub"><day>29</day><month>5</month><year>2018</year></pub-date><pub-date pub-type="pmc-release"><day>29</day><month>5</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>16</volume><elocation-id>142</elocation-id><history><date date-type="received"><day>27</day><month>4</month><year>2018</year></date><date date-type="accepted"><day>7</day><month>5</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2018</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Standard therapy for glioblastoma includes surgery, radiotherapy, and temozolomide. This Phase 3 trial evaluates the addition of an autologous tumor lysate-pulsed dendritic cell vaccine (DCVax<sup>&#x000ae;</sup>-L) to standard therapy for newly diagnosed glioblastoma.</p></sec><sec><title>Methods</title><p id="Par2">After surgery and chemoradiotherapy, patients were randomized (2:1) to receive temozolomide plus DCVax-L (n&#x02009;=&#x02009;232) or temozolomide and placebo (n&#x02009;=&#x02009;99). Following recurrence, all patients were allowed to receive DCVax-L, without unblinding. The primary endpoint was progression free survival (PFS); the&#x000a0;secondary endpoint was overall survival (OS).</p></sec><sec><title>Results</title><p id="Par3">For the intent-to-treat (ITT) population (n&#x02009;=&#x02009;331), median OS (mOS) was 23.1&#x000a0;months from surgery. Because of the cross-over trial design, nearly 90% of the ITT population received DCVax-L. For patients with methylated MGMT (n&#x02009;=&#x02009;131), mOS was 34.7&#x000a0;months from surgery, with a 3-year survival of 46.4%. As of this analysis, 223 patients are&#x02009;&#x02265;&#x02009;30&#x000a0;months past their surgery date; 67 of these (30.0%) have lived&#x02009;&#x02265;&#x02009;30&#x000a0;months and have a Kaplan-Meier (KM)-derived&#x000a0;mOS of 46.5&#x000a0;months. 182 patients are&#x02009;&#x02265;&#x02009;36&#x000a0;months past surgery; 44 of these (24.2%) have lived&#x02009;&#x02265;&#x02009;36&#x000a0;months and have a KM-derived mOS of 88.2&#x000a0;months. A population of extended survivors (n&#x02009;=&#x02009;100) with mOS of 40.5&#x000a0;months, not explained by known prognostic factors, will be analyzed further. Only 2.1% of ITT patients (n&#x02009;=&#x02009;7) had a grade 3 or 4 adverse event that was deemed at least possibly related to the vaccine. Overall adverse events with DCVax were comparable to standard therapy alone.</p></sec><sec><title>Conclusions</title><p id="Par4">Addition of DCVax-L to standard therapy is feasible and safe in glioblastoma patients, and may extend survival.</p><p id="Par5"><italic>Trial registration</italic> Funded by Northwest Biotherapeutics; Clinicaltrials.gov number: NCT00045968; <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT00045968?term=NCT00045968&#x00026;rank=1">https://clinicaltrials.gov/ct2/show/NCT00045968?term=NCT00045968&#x00026;rank=1</ext-link>; initially registered 19 September 2002</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Glioblastoma</kwd><kwd>Immunotherapy</kwd><kwd>Dendritic cell</kwd><kwd>Vaccine</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2018</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par6">Glioblastoma is the most aggressive primary malignant brain tumor in adults [<xref ref-type="bibr" rid="CR1">1</xref>]. Standard of care (SOC) consists of surgical resection followed by 6&#x000a0;weeks of daily radiotherapy with concurrent temozolomide, then monthly temozolomide [<xref ref-type="bibr" rid="CR2">2</xref>]. Median overall survival (mOS) under this SOC is only 15&#x02013;17&#x000a0;months [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>], and&#x02009;&#x02264;&#x02009;5% of patients are alive at 5&#x000a0;years [<xref ref-type="bibr" rid="CR3">3</xref>]. Loco-regional therapy with alternating electric fields has recently shown an increase in median PFS (mPFS) to 6.7&#x000a0;months and mOS to 20.9&#x000a0;months from randomization, respectively [<xref ref-type="bibr" rid="CR4">4</xref>]. However, there has been no material advance in survival with systemic therapies since the addition of temozolomide 12&#x000a0;years ago, despite investigations with many diverse agents [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR5">5</xref>&#x02013;<xref ref-type="bibr" rid="CR10">10</xref>].</p><p id="Par7">Immunotherapy is an appealing strategy because of the potential ability for immune cells to traffic to and destroy infiltrating tumor cells. Dendritic cells (DCs) are central to the immune system as key regulators of immune tolerance and immunity [<xref ref-type="bibr" rid="CR11">11</xref>]. For more than a decade, our group and others have been testing active vaccination strategies, such as DCs pulsed with tumor lysates or synthetic peptides to induce antitumor immunity in glioblastoma patients [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. We have previously demonstrated the effectiveness of DC vaccination in pre-clinical models [<xref ref-type="bibr" rid="CR14">14</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref>], and early stage clinical trials have shown substantial promise [<xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR19">19</xref>].</p><p id="Par8">In this report, we describe the blinded interim data of the overall ITT patient population enrolled in a Phase 3 randomized, double-blinded, placebo-controlled clinical trial of an autologous tumor lysate-pulsed dendritic cell vaccine (DCVax<sup>&#x000ae;</sup>-L) for newly diagnosed glioblastoma. To date, we have not yet reached sufficient events (i.e., deaths) in this trial to justify unblinding. Nevertheless, since the vast majority (86.4%) of the ITT population received the experimental DC treatment at some point during the trial because of the cross-over study design, analysis of the interim data may provide early insight into the impact of DCVax-L on overall survival. A final analysis of the data obtained in this trial following unblinding will occur once sufficient events of disease progression or death have occurred to fully elucidate patient survival data in the tail of the survival curve.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Study patients</title><p id="Par9">Patients were eligible for this study if they were 18&#x02013;70&#x000a0;years of age and had newly diagnosed glioblastoma, as determined through central pathology review. Other eligibility criteria included Karnofsky Performance Score (KPS) of&#x02009;&#x02265;&#x02009;70 [<xref ref-type="bibr" rid="CR20">20</xref>], adequate bone marrow, liver, and renal function, life expectancy of&#x02009;&#x02265;&#x02009;8&#x000a0;weeks, no other prior malignancy within the last 5&#x000a0;years, no active viral infections, and sufficient resected tumor material to produce the autologous vaccine. Patients were excluded if they already had apparent early disease progression/recurrence or pseudo-progression at the baseline visit, similar to the inclusion/exclusion criteria of other recent trials in glioblastoma [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR21">21</xref>].</p></sec><sec id="Sec4"><title>Study design and treatments</title><p id="Par10">We conducted this study at over 80 sites in 4 countries: the US, Canada, Germany, and the UK. Patient recruitment was initiated in 2007, and was paused from 2009 to 2011 for economic reasons. The midpoint of enrollment was reached in May of 2014, and the final patient was enrolled in November of 2015. The protocol was approved by the required independent ethics committees and institutional review boards. Written consent was obtained from all patients participating in the trial.</p><p id="Par11">All patients underwent surgical resection and 6&#x000a0;weeks of chemoradiotherapy per SOC, prior to enrollment and randomization in the study.</p><p id="Par12">Randomization was performed centrally and was stratified by clinical site and MGMT (O<sup>6</sup>-methylguanine-DNA methyltransferase) gene promoter methylation status, which was determined by a central laboratory. Patients were randomized 2:1 to SOC plus autologous DC vaccine (DCVax-L; n&#x02009;=&#x02009;232) or SOC plus placebo (n&#x02009;=&#x02009;99). PBMCs were used as placebo control as these cells are visually indistinguishable from DC and are considered immunologically inactive. Patients in both arms continued to receive monthly adjuvant temozolomide (150&#x02013;200&#x000a0;mg/m<sup>2</sup>/day&#x02009;&#x000d7;&#x02009;5&#x000a0;days every 28&#x000a0;days), interspersed with the DC vaccine or placebo treatments administered on Days 0, 10 and 20, then Months 2, 4 and 8, and thereafter at 6-month intervals starting at month 12. Each DCVax-L treatment involved a dose of 2.5 million autologous tumor lysate-pulsed DCs administered intradermally in the upper arm, alternating arms between injection visits.</p><p id="Par13">All patients were allowed to receive DCVax-L following tumor progression/recurrence, as well as other approved treatments per local practice. All parties (investigators, patients and sponsor) remained blinded as to which treatment each patient had received prior to crossover. All patients who chose this option were given the active treatment on a re-start schedule with immunizations at Days 0, 10 and 20, and then months 2, 4 and 8, and every 6&#x000a0;months thereafter beginning with month 12, with Day 0 being the day of the first vaccination post progression. To date, DCVax-L has been shipped for 286 patients (86.4%) in the trial.</p><p id="Par14">Both the study treatment (DCVax-L) and placebo (PBMC) were prepared by Cognate BioServices, Inc. for all patients in the US and Canada, and by Cognate and the Fraunhofer Institute for Cell Therapy together for patients in Europe, during the chemoradiotherapy period before the baseline visit. The production of DCVax-L involved processing the resected tumor tissue into a lysate, and then collection, purification, differentiation, activation and loading of the autologous DCs. In general, approximately 2&#x000a0;g of tumor tissue was needed to produce the full ten doses for the 36-month treatment and follow-up schedule. The vaccine was aliquoted in individual doses and cryopreserved at&#x02009;&#x0003c;&#x02009;150&#x000a0;&#x000b0;C [<xref ref-type="bibr" rid="CR22">22</xref>]. The doses were stored centrally, and shipped individually to the clinical trial sites.</p></sec><sec id="Sec5"><title>Assessments</title><p id="Par15">Baseline assessments included physical examination, neurological examination, vitals, KPS, MRI of brain with and without contrast, hematology (CBC with differential, platelets), and serum chemistries (calcium, magnesium, SGOT, SGPT, alkaline phosphatase, LDH, total bilirubin, BUN, creatinine, electrolytes, glucose). Blood was collected for serum markers of autoimmune disease (anti-DNA) and immune monitoring, at the baseline visit and at treatment visits throughout the trial. MRI brain scans were performed every 2&#x000a0;months, per SOC, after the baseline MRI until radiological tumor progression. All MRI scans were evaluated centrally by 2 blinded independent radiologists, with adjudication by a third such radiologist if needed.</p><p id="Par16">Adverse events were recorded prospectively according to the National Cancer Institute&#x02019;s Common Terminology Criteria (version 3.0 NCI CTC), until 2&#x000a0;months after the last study treatment. Patients are followed for OS until death.</p></sec><sec id="Sec6"><title>Statistical analyses</title><p id="Par17">The study&#x02019;s primary endpoint is&#x000a0;PFS, and the secondary endpoint is OS. PFS has not yet been evaluated for this publication and will be the subject of later analyses to allow for central, multi-factorial assessment by an expert panel, using criteria currently emerging as appropriate for immune therapy in this patient population where progression can be complex to determine and pseudo-progression is a known confounding phenomenon. Analysis of the blinded interim data on OS of the ITT population (using SAS version 9.4) was performed 34&#x000a0;months after the midpoint of patient enrollment, and 16&#x000a0;months after the last patient was enrolled and randomized.</p><p id="Par18">General descriptive statistics include the number of observed values, mean, standard deviation, median, and range values for continuous measures. For categorical variables, the number and percentage of subjects with a specific level of the variable are reported. For survival analyses, Kaplan&#x02013;Meier (KM) curves were generated, yielding estimates of median survival times, along with the two-sided confidence intervals (95% CIs) and estimates of survival at specific time points.</p></sec></sec><sec id="Sec7"><title>Results</title><sec id="Sec8"><title>Study patients</title><p id="Par19">From July 2007 to November 2015, 331 patients were recruited in the trial, comprising the intent-to-treat (ITT) population. A flow diagram depicting the flow of patients through the screening and enrollment process is provided in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>. The median time from surgery to randomization was 3.1&#x000a0;months.<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Recruitment, inclusion, and randomization of patients in the study. (1) Patients are screened prior to surgery, so glioblastoma (GBM) determination is made from pathological diagnosis after surgery. (2) Insufficient tumor lysate generated to meet threshold. (3) Progressive disease or pseudo-progression (which are indistinguishable at this point) based on central review of MRI imaging at baseline post-chemoradiation. (4) Patients who consented to tumor donation but then declined participation in trial prior to leukapheresis. (5) Includes deviations from standard chemoradiation protocol, history of prior malignancy, inadequate renal or bone marrow function, etc. (6) Includes drug product failure or insufficient drug or placebo manufactured to meet release criteria. (7) Includes clinical deterioration, declining Karnofsky performance status, or patient deaths. (8) Includes biopsy only, surgery canceled, or tumor tissue not processed after surgery</p></caption><graphic xlink:href="12967_2018_1507_Fig1_HTML" id="MO1"/></fig></p><p id="Par20">The ITT population (n&#x02009;=&#x02009;331) (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>) is similar to other recent glioblastoma trials [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR24">24</xref>], with 61% males (n&#x02009;=&#x02009;202) and 39% females (n&#x02009;=&#x02009;129), with 75.2% of the patients&#x02009;&#x02265;&#x02009;50&#x000a0;years of age (range 19&#x02013;73&#x000a0;years), and median KPS of 90. 63.1% of patients (n&#x02009;=&#x02009;209) had gross total resection and 36.9% (n&#x02009;=&#x02009;122) did not. The MGMT gene promoter was methylated in 39.6% of patients (n&#x02009;=&#x02009;131) and unmethylated in 48.9% (n&#x02009;=&#x02009;162), with information not available for 11.5% (n&#x02009;=&#x02009;38; the missing data relates to the early patients enrolled a decade ago). Absolute lymphocyte count (ALC) was&#x02009;&#x0003e;&#x02009;800&#x000a0;cells/mm<sup>3</sup> in 48.6% of the patients (n&#x02009;=&#x02009;161) and was&#x02009;&#x0003c;&#x02009;800&#x000a0;cells/mm<sup>3</sup> in 51.4% of patients (n&#x02009;=&#x02009;170), a characteristic that has been associated with poor prognosis after radiation [<xref ref-type="bibr" rid="CR23">23</xref>]. Patients with radiographic evidence of disease progression at baseline were excluded, as they have also been excluded in other recent trials for newly diagnosed glioblastoma [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR24">24</xref>].<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Baseline demographic and clinical characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Variable</th><th align="left">n&#x02009;=&#x02009;331 (100%)</th></tr></thead><tbody><tr><td align="left" colspan="2">Age (year)</td></tr><tr><td align="left">&#x000a0;Mean (SD)</td><td char="(" align="char">55.33 (10.01)</td></tr><tr><td align="left">&#x000a0;Median (range)</td><td char="(" align="char">56 (19, 73)</td></tr><tr><td align="left" colspan="2">Sex, n (%)</td></tr><tr><td align="left">&#x000a0;Female</td><td char="(" align="char">129 (39.0)</td></tr><tr><td align="left">&#x000a0;Male</td><td char="(" align="char">202 (61.0)</td></tr><tr><td align="left" colspan="2">Race, n (%)</td></tr><tr><td align="left">&#x000a0;American Indian or Alaska Native</td><td char="(" align="char">1 (0.3)</td></tr><tr><td align="left">&#x000a0;Asian</td><td char="(" align="char">2 (0.6)</td></tr><tr><td align="left">&#x000a0;Black or African American</td><td char="(" align="char">7 (2.1)</td></tr><tr><td align="left">&#x000a0;Hispanic or Latino</td><td char="(" align="char">16 (4.8)</td></tr><tr><td align="left">&#x000a0;White</td><td char="(" align="char">294 (88.8)</td></tr><tr><td align="left">&#x000a0;Not available<sup>a</sup></td><td char="(" align="char">11 (3.3)</td></tr><tr><td align="left" colspan="2">KPS at baseline, n (%)</td></tr><tr><td align="left">&#x000a0;&#x0003c;&#x02009;90</td><td char="(" align="char">97 (29.3)</td></tr><tr><td align="left">&#x000a0;&#x02265;&#x02009;90</td><td char="(" align="char">234 (70.7)</td></tr><tr><td align="left" colspan="2">MGMT classification, n (%)</td></tr><tr><td align="left">&#x000a0;Methylated</td><td char="(" align="char">131 (39.6)</td></tr><tr><td align="left">&#x000a0;Not methylated</td><td char="(" align="char">162 (48.9)</td></tr><tr><td align="left">&#x000a0;Not available</td><td char="(" align="char">38 (11.5)</td></tr><tr><td align="left" colspan="2">Lymphocyte group, n (%)</td></tr><tr><td align="left">&#x000a0;High</td><td char="(" align="char">161 (48.6)</td></tr><tr><td align="left">&#x000a0;Low</td><td char="(" align="char">170 (51.4)</td></tr><tr><td align="left" colspan="2">Surgical status, n (%)</td></tr><tr><td align="left">&#x000a0;Partial resection</td><td char="(" align="char">122 (36.9)</td></tr><tr><td align="left">&#x000a0;Complete resection</td><td char="(" align="char">209 (63.1)</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Race is in some cases not collected due to institutional policy</p></table-wrap-foot></table-wrap></p><p id="Par21">Since other treatments were allowed following disease progression, we assessed their usage in this trial. While on study, three patients (1%) had another resection, 103 patients (31%) received bevacizumab, 53 patients (16%) received CCNU and 6 patients (1.8%) were treated with tumor treating fields. In multiple reported studies, neither bevacizumab nor CCNU have been shown to extend survival [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR25">25</xref>].</p></sec><sec id="Sec9"><title>Treatment outcomes</title><sec id="Sec10"><title>ITT population</title><p id="Par22">At the time of this analysis, 108 the 331 patients (32.6%) were still alive. The mOS of the overall ITT population (n&#x02009;=&#x02009;331) was 23.1&#x000a0;months from the time of surgery (95% CI 21.2&#x02013;25.4), with 2 and 3-year survival rates of 46.2 and 25.4%, respectively (see Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>a&#x000a0;and Table <xref rid="Tab2" ref-type="table">2</xref>). Analysis of patient survival relative to year of enrollment did not reveal a trend over time, nor meaningful differences between years.<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Overall survival curves for patients in the intent-to-treat population. Overall survival analyses of time from date of surgery until death or last follow-up according to the Kaplan&#x02013;Meier method for all patients in the intent-to-treat (ITT) population (<bold>a</bold>), and the ITT population stratified by MGMT gene promoter methylation status (<bold>b</bold>). Censored patients are annotated by a small vertical line</p></caption><graphic xlink:href="12967_2018_1507_Fig2_HTML" id="MO2"/></fig><table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Study endpoints according to molecular genetic and clinical prognostic subgroups</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Population</th><th align="left">n</th><th align="left">Median OS since surgery (months)<sup>a</sup></th><th align="left">Survival at 1&#x000a0;year<sup>b</sup></th><th align="left">Survival at 2&#x000a0;years<sup>b</sup></th><th align="left">Survival at 3&#x000a0;years<sup>b</sup></th></tr></thead><tbody><tr><td align="left">Overall</td><td char="." align="char">331</td><td align="left">23.1<break/>(21.2, 25.4)</td><td align="left">89.3%<break/>(85.4, 92.2)</td><td align="left">46.2%<break/>(40.4, 51.8)</td><td align="left">25.4%<break/>(19.9, 31.3)</td></tr><tr><td align="left">MGMT methylated</td><td char="." align="char">131</td><td align="left">34.7<break/>(27.0, 40.7)</td><td align="left">94.5%<break/>(88.8, 97.3)</td><td align="left">66.7%<break/>(57.5, 74.4)</td><td align="left">46.4%<break/>(35.8, 56.3)</td></tr><tr><td align="left">MGMT un-methylated</td><td char="." align="char">162</td><td align="left">19.8<break/>(17.9, 21.7)</td><td align="left">86.4%<break/>(80.0, 90.8)</td><td align="left">32.1%<break/>(24.5, 9.9)</td><td align="left">11.0%<break/>(5.7, 18.2)</td></tr><tr><td align="left">Gross total resection</td><td char="." align="char">209</td><td align="left">25.4<break/>(21.8, 28.2)</td><td align="left">91.8%<break/>(87.1, 94.8)</td><td align="left">51.2%<break/>(43.9, 58.1)</td><td align="left">29.9%<break/>(22.6, 37.5)</td></tr><tr><td align="left">Partial resection</td><td char="." align="char">122</td><td align="left">21.1<break/>(19.1, 23.1)</td><td align="left">85.0%<break/>(77.2, 90.2)</td><td align="left">37.7%<break/>(28.6, 46.7)</td><td align="left">18.0%<break/>(10.5, 27.1)</td></tr><tr><td align="left">KPS at baseline &#x02265;&#x02009;90</td><td char="." align="char">234</td><td align="left">23.7<break/>(21.8, 26.7)</td><td align="left">94.0%<break/>(90.0, 96.4)</td><td align="left">49.2%<break/>(42.3, 55.8)</td><td align="left">26.6%<break/>(19.9, 33.8)</td></tr><tr><td align="left">KPS at baseline &#x0003c;&#x02009;90</td><td char="." align="char">97</td><td align="left">19.8<break/>(16.6, 23.9)</td><td align="left">77.8%<break/>(68.0, 84.9)</td><td align="left">38.8%<break/>(28.5, 49.0)</td><td align="left">22.1%<break/>(13.4, 32.2)</td></tr><tr><td align="left">ALC&#x02009;&#x0003e;&#x02009;800</td><td char="." align="char">161</td><td align="left">23.6<break/>(21.7, 28.2)</td><td align="left">89.9%<break/>(84.0, 93.7)</td><td align="left">49.5%<break/>(41.1, 57.4)</td><td align="left">28.7%<break/>(20.6, 37.3)</td></tr><tr><td align="left">ALC&#x02009;&#x02264;&#x02009;800</td><td char="." align="char">170</td><td align="left">21.6<break/>(19.9, 25.2)</td><td align="left">88.7%<break/>(82.8, 92.6)</td><td align="left">43.3%<break/>(35.4, 50.9)</td><td align="left">22.2%<break/>(15.0, 30.3)</td></tr><tr><td align="left">Age&#x02009;&#x0003c;&#x02009;50&#x000a0;years</td><td char="." align="char">82</td><td align="left">26.2<break/>(21.1, 31.5)</td><td align="left">92.5%<break/>(84.2, 96.6)</td><td align="left">51.7%<break/>(39.9, 62.3)</td><td align="left">28.0%<break/>(16.4, 40.8)</td></tr><tr><td align="left">Age&#x02009;&#x02265;&#x02009;50&#x000a0;years</td><td char="." align="char">249</td><td align="left">22.4<break/>(20.4, 24.1)</td><td align="left">88.2%<break/>(83.5, 91.7)</td><td align="left">44.4%<break/>(37.7, 50.8)</td><td align="left">24.6%<break/>(18.5, 31.2)</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Median overall survival (OS) in months of intent-to-treat (ITT) population, followed by 95% confidence interval in parentheses</p><p><sup>b</sup>Annual rates of percentage surviving in ITT population, followed by 95% confidence interval in parentheses</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec11"><title>Long tail among ITT population</title><p id="Par23">With immune-based therapies, a key focus is on the tail of the survival curve [<xref ref-type="bibr" rid="CR26">26</xref>]. Among the ITT patients with a surgery date&#x02009;&#x02265;&#x02009;30&#x000a0;months prior to the data collection (n = 223), 30% (n = 67) have lived&#x02009;&#x02265;&#x02009;30&#x000a0;months, and their KM-derived mOS estimate is 46.5&#x000a0;months. Among the ITT patients with a surgery date &#x02265; 36&#x000a0;months prior to the data collection&#x000a0;(n = 182), 24.2% (n =&#x000a0;44)&#x000a0;have lived &#x02265; 36&#x000a0;months and their KM-derived mOS estimate is 88.2&#x000a0;months.</p></sec><sec id="Sec12"><title>MGMT status and extent of resection</title><p id="Par24">In patients with methylated MGMT (n&#x02009;=&#x02009;131), mOS was 34.7&#x000a0;months from surgery (95% CI 27.0&#x02013;40.7), with 2 and 3-year survival rates of 66.7% and 46.4%, respectively. In patients with unmethylated MGMT (n&#x02009;=&#x02009;162), mOS was 19.8&#x000a0;months from surgery (95% CI 17.9&#x02013;21.7), with 2 and 3-year survival rates of 32.1%, and 11.0%, respectively (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>b and Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).</p><p id="Par25">For patients with gross total surgical resection (n&#x02009;=&#x02009;209), mOS was 25.4&#x000a0;months from surgery (95% CI 21.8&#x02013;28.2), with 2 and 3-year survival rates of 51.2%, and 29.9%, respectively. For patients with only partial surgical resection (n&#x02009;=&#x02009;122), mOS from surgery was 21.1&#x000a0;months (95% CI 19.1&#x02013;23.1), with 2 and 3-year survival rates of 37.7%, and 18.0%, respectively (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).</p><p id="Par26">In patients with both MGMT methylation and gross total resection (n&#x02009;=&#x02009;83), the mOS was 36.5&#x000a0;months (95% CI 31.5&#x02013;46.5)&#x02014;1.8&#x000a0;months longer than the mOS of patients with MGMT methylation and only partial resection (n&#x02009;=&#x02009;48). In patients with unmethylated MGMT, there was no statistically significant survival advantage with gross total resection compared to only partial resection.</p></sec><sec id="Sec13"><title>Unknown factors: sub-group with extended survival</title><p id="Par27">Approximately 30% of the ITT population (n&#x02009;=&#x02009;100) showed particularly extended survival, with a KM derived mOS estimate of 40.5&#x000a0;months. This is not fully explained by known prognostic factors, as only some of these patients had positive prognostic factors: only 29% were younger than 50&#x000a0;years of age, 65.9% had methylated MGMT, 71% had a complete resection, and only 8% of these patients had all three positive prognostic factors. These patients will be the subject of extensive further analyses and research.</p></sec></sec><sec id="Sec14"><title>Safety and toxicity</title><p id="Par28">Safety and toxicity data were assessed on a blinded basis for all 331 ITT patients. Following SOC chemoradiotherapy, and before any DCVax-L treatment, lymphopenia was the most common adverse event, occurring in approximately 170 patients (51%) [<xref ref-type="bibr" rid="CR23">23</xref>].</p><p id="Par29">The DCVax-L treatment was well tolerated, with only 7 ITT patients (2.1%) experiencing serious (NCI CTC Grades 3&#x02013;4) adverse events that were deemed related or possibly related to the DCVax-L treatment. These included cerebral edema in 3 patients (0.9%), seizures in 2 patients (0.6%), nausea in 1 patient (0.3%) and lymph gland infection in 1 patient (0.3%).</p><p id="Par30">The rate of total adverse events with SOC plus DCVax-L was comparable to SOC alone (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). Non-serious adverse events that were considered possibly related to the treatment included injection site reactions, fatigue, low-grade fever and night chills.<table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Grades 3&#x02013;4 treatment-emergent adverse events (TEAE)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">System organ class<sup>a</sup></th><th align="left">Number (%) of patients with TEAE (n&#x02009;=&#x02009;331)</th></tr></thead><tbody><tr><td align="left">Patients reporting at least one serious TEAE (whether or not related to DC vaccine treatment)</td><td char="(" align="char">137 (41.1%)</td></tr><tr><td align="left">Nervous system disorders</td><td char="(" align="char">93 (28.1%)</td></tr><tr><td align="left">Infections<sup>b</sup></td><td char="(" align="char">23 (6.9%)</td></tr><tr><td align="left">General disorders and injection site reactions</td><td char="(" align="char">22 (6.6%)</td></tr><tr><td align="left">Respiratory, thoracic and mediastinal disorders</td><td char="(" align="char">17 (5.1%)</td></tr><tr><td align="left">Psychiatric disorders</td><td char="(" align="char">16 (4.8%)</td></tr><tr><td align="left">Gastrointestinal disorders</td><td char="(" align="char">16 (4.8%)</td></tr><tr><td align="left">Injury, poisoning, and procedural complications</td><td char="(" align="char">12 (3.6%)</td></tr><tr><td align="left">Vascular disorders</td><td char="(" align="char">6 (1.8%)</td></tr><tr><td align="left">Musculoskeletal and connective tissue disorders</td><td char="(" align="char">5 (1.5%)</td></tr><tr><td align="left">Neoplasms benign, malignant and unspecified</td><td char="(" align="char">5 (1.5%)</td></tr><tr><td align="left">Hematological disorders</td><td char="(" align="char">5 (1.5%)</td></tr><tr><td align="left">Metabolism and nutrition disorders</td><td char="(" align="char">3 (0.9%)</td></tr><tr><td align="left">Hepatobiliary disorders</td><td char="(" align="char">2 (0.6%)</td></tr><tr><td align="left">Renal and urinary disorders</td><td char="(" align="char">2 (0.6%)</td></tr><tr><td align="left">Cardiac disorders</td><td char="(" align="char">1 (0.3%)</td></tr><tr><td align="left">Ear and labyrinth disorders</td><td char="(" align="char">1 (0.3%)</td></tr><tr><td align="left">Immune system disorders<sup>c</sup></td><td char="(" align="char">1 (0.3%)</td></tr><tr><td align="left">Reproductive system and breast disorders</td><td char="(" align="char">1 (0.3%)</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Coded per MedDRA 16.0. Patients may have had more than one adverse event, so subcategories do not total</p><p><sup>b</sup>Includes surgical wound infections, meningitis, urinary tract infections, and others</p><p><sup>c</sup>Includes drug hypersensitivity</p></table-wrap-foot></table-wrap>
</p></sec></sec><sec id="Sec15"><title>Discussion</title><p id="Par31">Although enrollment was completed in 2015, this trial, including both treatments and follow-up, is still ongoing and will remain blinded until sufficient events of disease progression and/or death have occurred to more fully elucidate the tail of the survival curve. To date, due to the crossover design, nearly 90% of the ITT population received DCVax-L at some point in the trial, due to the crossover design.</p><p id="Par32">DCVax-L is administered by intra-dermal injection in the arm, six times in year one and twice per year thereafter. It thereby imposes only a minimal burden on the patient.</p><p id="Par33">In the overall ITT population in this trial, the mOS of 23.1&#x000a0;months from surgery compares favorably with the mOS of 15&#x02013;17&#x000a0;months from surgery typically achieved with SOC in past studies and clinical practice, as well as with the survival data with SOC treatment in the control arms of other trials in similar patient populations. For example, Weller et al. reported mOS of 17.4&#x000a0;months from randomization in the ITT population [<xref ref-type="bibr" rid="CR21">21</xref>], and Stupp et al. reported mOS of 16.0&#x000a0;months from randomization in the ITT population [<xref ref-type="bibr" rid="CR24">24</xref>].</p><p id="Par34">In patients with a methylated MGMT gene promoter, the mOS of 34.7&#x000a0;months from surgery also compares favorably with SOC in past studies as well as with the mOS reported for the control arm SOC treatments in other recent glioblastoma trials in similar patient populations. For example, Stupp et al. reported for their control group an&#x000a0;mOS of 21.2&#x000a0;months from randomization in a similar patient population [<xref ref-type="bibr" rid="CR24">24</xref>]. The increase in survival in MGMT-methylated patients in the DCVax-L trial raises the possibility of a cooperative effect from the combination of temozolomide chemotherapy and the DCVax-L active immune therapy [<xref ref-type="bibr" rid="CR17">17</xref>].</p><p id="Par35">The mutation status of the IDH1 gene has not yet been investigated for this trial, as this factor was not included in trial designs a decade ago when this trial began. It will be collected and analyzed later, but is unlikely to explain the overall survival results, as the mutation associated with prolonged survival occurs in less than 10% of newly diagnosed glioblastoma patients [<xref ref-type="bibr" rid="CR27">27</xref>].</p><p id="Par36">Beneficial effects of immune therapies are often observed at later time points, in the tail of the survival curve [<xref ref-type="bibr" rid="CR26">26</xref>]. Although this Phase 3 trial requires further maturation, a picture is beginning to emerge from the blinded interim data which is consistent with an extended survival tail. For example, among the patients (n&#x02009;=&#x02009;182) who were&#x02009;&#x02265;&#x02009;36&#x000a0;months past their surgery date as of the date of this analysis, 24.2% (n&#x02009;=&#x02009;44) were alive for&#x02009;&#x02265;&#x02009;36&#x000a0;months and have a KM estimated median survival time of 88.2&#x000a0;months. Thus, it appears that patients who survive past certain threshold time points may continue onwards to unusually long survival times, similar to the findings in our prior Phase I/II studies of this DC-based vaccine [<xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR19">19</xref>]. Further maturation of the trial data is needed to more fully reveal the extent of the long tail of the survival curve.</p><p id="Par37">DCVax-L has shown a benign safety profile in this Phase 3 study, as it has consistently done in prior early stage trials [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR19">19</xref>], and in a large group of patients treated on a compassionate use basis [<xref ref-type="bibr" rid="CR28">28</xref>]. The fact that only 7 of the 331 ITT patients (2.1%) experienced any grade 3 or 4 adverse events that were at least possibly related to the treatment makes this DC vaccine an especially well tolerated treatment.</p><p id="Par38">With such a safety profile, this DC vaccine may be administered in a wide range of clinical settings, and can potentially be combined with a wide range of other treatment agents, including immune checkpoint inhibitors and targeted therapies, without resulting in undue toxicities for patients such as have been seen with some other treatment combinations [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. Further studies to explore such combinations are warranted.</p></sec><sec id="Sec16"><title>Conclusions</title><p id="Par39">The addition of DCVax-L autologous dendritic cell vaccine to SOC is feasible and safe. Collectively, the blinded interim survival data suggest that the patients in this Phase 3 trial are living longer than expected. These findings warrant further follow up and analyses.</p></sec></body><back><ack><title>Authors&#x02019; contributions</title><p>LL and MB conceived of and designed the study. LL, KA, DDT, JLC, TET, CSC, JAH, MS, ST, SDD, FMI, EJD, YAM, KAW, CPP, RA, RC, SAG, DAB, PD, JG, HE, SAT, KOL, TM, TW, SRA, AJB, SB, MGE, AK, JP, LJK, WGL, RCT, DEA, KLF, FJG, SL, JL, AES, GS, DK, H-JM, JW, RPD, CD, ABE, DM, SK, DP, MW, DSB, PZN, ML, S-AM, TJP, VT, RMG, JLV, MP, KP, MS, LPT, and PM contributed to collection of the data. EB served as the consulting statistician. All authors were involved in critical review of the data, or drafting, reviewing or revising the manuscript or approving the final version. LL enrolled the greatest number of patients in the USA and KA enrolled the greatest number of patients in the EU. All authors read and approved the final manuscript.</p><sec id="FPar1"><title>Acknowledgements</title><p id="Par40">Supported by Northwest Biotherapeutics, Inc. and the UCLA SPORE in Brain Cancer (P50-CA211015). We thank the patients who have participated in this clinical trial and their families.</p></sec><sec id="FPar2"><title>Competing interests</title><p id="Par41">Dr. Bosch and Dr. Maida report being an employee of, holding stock or stock options in, and receiving reimbursement for travel expenses from Northwest Biotherapeutics, Inc.</p></sec><sec id="FPar3"><title>Availability of data and materials</title><p id="Par42">The datasets generated and/or analyzed during the current study are not publicly available to protect future regulatory filings but access to the data can be available through an independent statistician on a case by case basis, as necessary and under confidentiality.</p></sec><sec id="FPar4"><title>Consent for publication</title><p id="Par43">Not applicable.</p></sec><sec id="FPar5"><title>Ethics approval and consent to participate</title><p id="Par44">The study was approved by Ethics Committees/Institutional Review boards at all participating hospitals. Written consent was obtained from all patients prior to participating in the study.</p></sec><sec id="FPar6"><title>Funding</title><p id="Par45">Northwest Biotherapeutics, Inc. was the trial sponsor and had a role in the design and conduct of the study, along with academic advisers; collection, management, analysis, and interpretation of the data; preparation, review, and approval of the manuscript; and decision to submit the manuscript for publication. Data collected by the CRO from the investigators and their site personnel were analyzed and interpreted on a blinded basis by senior academic authors, independent statisticians, and representatives of the sponsor.</p></sec><sec id="FPar7"><title>Publisher&#x02019;s Note</title><p id="Par46">Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ostrom</surname><given-names>QT</given-names></name><name><surname>Gittleman</surname><given-names>H</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Kromer</surname><given-names>C</given-names></name><name><surname>Wolinsky</surname><given-names>Y</given-names></name><name><surname>Kruchko</surname><given-names>C</given-names></name><name><surname>Barnholtz-Sloan</surname><given-names>JS</given-names></name></person-group><article-title>CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2009&#x02013;2013</article-title><source>Neuro-oncology</source><year>2016</year><volume>18</volume><issue>suppl_5</issue><fpage>v1</fpage><lpage>v75</lpage><pub-id pub-id-type="doi">10.1093/neuonc/now207</pub-id><pub-id pub-id-type="pmid">28475809</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stupp</surname><given-names>R</given-names></name><name><surname>Mason</surname><given-names>WP</given-names></name><name><surname>van den Bent</surname><given-names>MJ</given-names></name><name><surname>Weller</surname><given-names>M</given-names></name><name><surname>Fisher</surname><given-names>B</given-names></name><name><surname>Taphoorn</surname><given-names>MJ</given-names></name><name><surname>Belanger</surname><given-names>K</given-names></name><name><surname>Brandes</surname><given-names>AA</given-names></name><name><surname>Marosi</surname><given-names>C</given-names></name><name><surname>Bogdahn</surname><given-names>U</given-names></name><etal/></person-group><article-title>Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma</article-title><source>N Engl J Med</source><year>2005</year><volume>352</volume><issue>10</issue><fpage>987</fpage><lpage>996</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa043330</pub-id><pub-id pub-id-type="pmid">15758009</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stupp</surname><given-names>R</given-names></name><name><surname>Hegi</surname><given-names>ME</given-names></name><name><surname>Mason</surname><given-names>WP</given-names></name><name><surname>van den Bent</surname><given-names>MJ</given-names></name><name><surname>Taphoorn</surname><given-names>MJ</given-names></name><name><surname>Janzer</surname><given-names>RC</given-names></name><name><surname>Ludwin</surname><given-names>SK</given-names></name><name><surname>Allgeier</surname><given-names>A</given-names></name><name><surname>Fisher</surname><given-names>B</given-names></name><name><surname>Belanger</surname><given-names>K</given-names></name><etal/></person-group><article-title>Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial</article-title><source>Lancet Oncol</source><year>2009</year><volume>10</volume><issue>5</issue><fpage>459</fpage><lpage>466</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(09)70025-7</pub-id><pub-id pub-id-type="pmid">19269895</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stupp</surname><given-names>R</given-names></name><name><surname>Taillibert</surname><given-names>S</given-names></name><name><surname>Kanner</surname><given-names>AA</given-names></name><name><surname>Kesari</surname><given-names>S</given-names></name><name><surname>Steinberg</surname><given-names>DM</given-names></name><name><surname>Toms</surname><given-names>SA</given-names></name><name><surname>Taylor</surname><given-names>LP</given-names></name><name><surname>Lieberman</surname><given-names>F</given-names></name><name><surname>Silvani</surname><given-names>A</given-names></name><name><surname>Fink</surname><given-names>KL</given-names></name><etal/></person-group><article-title>Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial</article-title><source>JAMA</source><year>2015</year><volume>314</volume><issue>23</issue><fpage>2535</fpage><lpage>2543</lpage><pub-id pub-id-type="doi">10.1001/jama.2015.16669</pub-id><pub-id pub-id-type="pmid">26670971</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wick</surname><given-names>W</given-names></name><name><surname>Puduvalli</surname><given-names>VK</given-names></name><name><surname>Chamberlain</surname><given-names>MC</given-names></name><name><surname>van den Bent</surname><given-names>MJ</given-names></name><name><surname>Carpentier</surname><given-names>AF</given-names></name><name><surname>Cher</surname><given-names>LM</given-names></name><name><surname>Mason</surname><given-names>W</given-names></name><name><surname>Weller</surname><given-names>M</given-names></name><name><surname>Hong</surname><given-names>S</given-names></name><name><surname>Musib</surname><given-names>L</given-names></name><etal/></person-group><article-title>Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma</article-title><source>J Clin Oncol</source><year>2010</year><volume>28</volume><issue>7</issue><fpage>1168</fpage><lpage>1174</lpage><pub-id pub-id-type="doi">10.1200/JCO.2009.23.2595</pub-id><pub-id pub-id-type="pmid">20124186</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Batchelor</surname><given-names>TT</given-names></name><name><surname>Mulholland</surname><given-names>P</given-names></name><name><surname>Neyns</surname><given-names>B</given-names></name><name><surname>Nabors</surname><given-names>LB</given-names></name><name><surname>Campone</surname><given-names>M</given-names></name><name><surname>Wick</surname><given-names>A</given-names></name><name><surname>Mason</surname><given-names>W</given-names></name><name><surname>Mikkelsen</surname><given-names>T</given-names></name><name><surname>Phuphanich</surname><given-names>S</given-names></name><name><surname>Ashby</surname><given-names>LS</given-names></name><etal/></person-group><article-title>Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma</article-title><source>J Clin Oncol</source><year>2013</year><volume>31</volume><issue>26</issue><fpage>3212</fpage><lpage>3218</lpage><pub-id pub-id-type="doi">10.1200/JCO.2012.47.2464</pub-id><pub-id pub-id-type="pmid">23940216</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stupp</surname><given-names>R</given-names></name><name><surname>Hegi</surname><given-names>ME</given-names></name><name><surname>Gorlia</surname><given-names>T</given-names></name><name><surname>Erridge</surname><given-names>SC</given-names></name><name><surname>Perry</surname><given-names>J</given-names></name><name><surname>Hong</surname><given-names>YK</given-names></name><name><surname>Aldape</surname><given-names>KD</given-names></name><name><surname>Lhermitte</surname><given-names>B</given-names></name><name><surname>Pietsch</surname><given-names>T</given-names></name><name><surname>Grujicic</surname><given-names>D</given-names></name><etal/></person-group><article-title>Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial</article-title><source>Lancet Oncol</source><year>2014</year><volume>15</volume><issue>10</issue><fpage>1100</fpage><lpage>1108</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(14)70379-1</pub-id><pub-id pub-id-type="pmid">25163906</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilbert</surname><given-names>MR</given-names></name><name><surname>Dignam</surname><given-names>JJ</given-names></name><name><surname>Armstrong</surname><given-names>TS</given-names></name><name><surname>Wefel</surname><given-names>JS</given-names></name><name><surname>Blumenthal</surname><given-names>DT</given-names></name><name><surname>Vogelbaum</surname><given-names>MA</given-names></name><name><surname>Colman</surname><given-names>H</given-names></name><name><surname>Chakravarti</surname><given-names>A</given-names></name><name><surname>Pugh</surname><given-names>S</given-names></name><name><surname>Won</surname><given-names>M</given-names></name><etal/></person-group><article-title>A randomized trial of bevacizumab for newly diagnosed glioblastoma</article-title><source>N Engl J Med</source><year>2014</year><volume>370</volume><issue>8</issue><fpage>699</fpage><lpage>708</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1308573</pub-id><pub-id pub-id-type="pmid">24552317</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chinot</surname><given-names>OL</given-names></name><name><surname>Wick</surname><given-names>W</given-names></name><name><surname>Mason</surname><given-names>W</given-names></name><name><surname>Henriksson</surname><given-names>R</given-names></name><name><surname>Saran</surname><given-names>F</given-names></name><name><surname>Nishikawa</surname><given-names>R</given-names></name><name><surname>Carpentier</surname><given-names>AF</given-names></name><name><surname>Hoang-Xuan</surname><given-names>K</given-names></name><name><surname>Kavan</surname><given-names>P</given-names></name><name><surname>Cernea</surname><given-names>D</given-names></name><etal/></person-group><article-title>Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma</article-title><source>N Engl J Med</source><year>2014</year><volume>370</volume><issue>8</issue><fpage>709</fpage><lpage>722</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1308345</pub-id><pub-id pub-id-type="pmid">24552318</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Westphal</surname><given-names>M</given-names></name><name><surname>Heese</surname><given-names>O</given-names></name><name><surname>Steinbach</surname><given-names>JP</given-names></name><name><surname>Schnell</surname><given-names>O</given-names></name><name><surname>Schackert</surname><given-names>G</given-names></name><name><surname>Mehdorn</surname><given-names>M</given-names></name><name><surname>Schulz</surname><given-names>D</given-names></name><name><surname>Simon</surname><given-names>M</given-names></name><name><surname>Schlegel</surname><given-names>U</given-names></name><name><surname>Senft</surname><given-names>C</given-names></name><etal/></person-group><article-title>A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma</article-title><source>Eur J Cancer</source><year>2015</year><volume>51</volume><issue>4</issue><fpage>522</fpage><lpage>532</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2014.12.019</pub-id><pub-id pub-id-type="pmid">25616647</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palucka</surname><given-names>K</given-names></name><name><surname>Banchereau</surname><given-names>J</given-names></name></person-group><article-title>Cancer immunotherapy via dendritic cells</article-title><source>Nat Rev Cancer</source><year>2012</year><volume>12</volume><issue>4</issue><fpage>265</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.1038/nrc3258</pub-id><pub-id pub-id-type="pmid">22437871</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hickey</surname><given-names>MJ</given-names></name><name><surname>Malone</surname><given-names>CC</given-names></name><name><surname>Erickson</surname><given-names>KL</given-names></name><name><surname>Jadus</surname><given-names>MR</given-names></name><name><surname>Prins</surname><given-names>RM</given-names></name><name><surname>Liau</surname><given-names>LM</given-names></name><name><surname>Kruse</surname><given-names>CA</given-names></name></person-group><article-title>Cellular and vaccine therapeutic approaches for gliomas</article-title><source>J Transl Med</source><year>2010</year><volume>8</volume><fpage>100</fpage><pub-id pub-id-type="doi">10.1186/1479-5876-8-100</pub-id><pub-id pub-id-type="pmid">20946667</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prins</surname><given-names>RM</given-names></name><name><surname>Liau</surname><given-names>LM</given-names></name></person-group><article-title>Cellular immunity and immunotherapy of brain tumors</article-title><source>Front Biosci</source><year>2004</year><volume>9</volume><fpage>3124</fpage><lpage>3136</lpage><pub-id pub-id-type="doi">10.2741/1465</pub-id><pub-id pub-id-type="pmid">15353342</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liau</surname><given-names>LM</given-names></name><name><surname>Black</surname><given-names>KL</given-names></name><name><surname>Prins</surname><given-names>RM</given-names></name><name><surname>Sykes</surname><given-names>SN</given-names></name><name><surname>DiPatre</surname><given-names>PL</given-names></name><name><surname>Cloughesy</surname><given-names>TF</given-names></name><name><surname>Becker</surname><given-names>DP</given-names></name><name><surname>Bronstein</surname><given-names>JM</given-names></name></person-group><article-title>Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens</article-title><source>J Neurosurg</source><year>1999</year><volume>90</volume><issue>6</issue><fpage>1115</fpage><lpage>1124</lpage><pub-id pub-id-type="doi">10.3171/jns.1999.90.6.1115</pub-id><pub-id pub-id-type="pmid">10350260</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prins</surname><given-names>RM</given-names></name><name><surname>Craft</surname><given-names>N</given-names></name><name><surname>Bruhn</surname><given-names>KW</given-names></name><name><surname>Khan-Farooqi</surname><given-names>H</given-names></name><name><surname>Koya</surname><given-names>RC</given-names></name><name><surname>Stripecke</surname><given-names>R</given-names></name><name><surname>Miller</surname><given-names>JF</given-names></name><name><surname>Liau</surname><given-names>LM</given-names></name></person-group><article-title>The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity</article-title><source>J Immunol</source><year>2006</year><volume>176</volume><issue>1</issue><fpage>157</fpage><lpage>164</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.176.1.157</pub-id><pub-id pub-id-type="pmid">16365406</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prins</surname><given-names>RM</given-names></name><name><surname>Odesa</surname><given-names>SK</given-names></name><name><surname>Liau</surname><given-names>LM</given-names></name></person-group><article-title>Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model</article-title><source>Cancer Res</source><year>2003</year><volume>63</volume><issue>23</issue><fpage>8487</fpage><lpage>8491</lpage><pub-id pub-id-type="pmid">14679014</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liau</surname><given-names>LM</given-names></name><name><surname>Prins</surname><given-names>RM</given-names></name><name><surname>Kiertscher</surname><given-names>SM</given-names></name><name><surname>Odesa</surname><given-names>SK</given-names></name><name><surname>Kremen</surname><given-names>TJ</given-names></name><name><surname>Giovannone</surname><given-names>AJ</given-names></name><name><surname>Lin</surname><given-names>JW</given-names></name><name><surname>Chute</surname><given-names>DJ</given-names></name><name><surname>Mischel</surname><given-names>PS</given-names></name><name><surname>Cloughesy</surname><given-names>TF</given-names></name><etal/></person-group><article-title>Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment</article-title><source>Clin Cancer Res</source><year>2005</year><volume>11</volume><issue>15</issue><fpage>5515</fpage><lpage>5525</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-05-0464</pub-id><pub-id pub-id-type="pmid">16061868</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prins</surname><given-names>RM</given-names></name><name><surname>Cloughesy</surname><given-names>TF</given-names></name><name><surname>Liau</surname><given-names>LM</given-names></name></person-group><article-title>Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate</article-title><source>N Engl J Med</source><year>2008</year><volume>359</volume><issue>5</issue><fpage>539</fpage><lpage>541</lpage><pub-id pub-id-type="doi">10.1056/NEJMc0804818</pub-id><pub-id pub-id-type="pmid">18669440</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prins</surname><given-names>RM</given-names></name><name><surname>Soto</surname><given-names>H</given-names></name><name><surname>Konkankit</surname><given-names>V</given-names></name><name><surname>Odesa</surname><given-names>SK</given-names></name><name><surname>Eskin</surname><given-names>A</given-names></name><name><surname>Yong</surname><given-names>WH</given-names></name><name><surname>Nelson</surname><given-names>SF</given-names></name><name><surname>Liau</surname><given-names>LM</given-names></name></person-group><article-title>Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy</article-title><source>Clin Cancer Res</source><year>2011</year><volume>17</volume><issue>6</issue><fpage>1603</fpage><lpage>1615</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-10-2563</pub-id><pub-id pub-id-type="pmid">21135147</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Curran</surname><given-names>WJ</given-names><suffix>Jr</suffix></name><name><surname>Scott</surname><given-names>CB</given-names></name><name><surname>Horton</surname><given-names>J</given-names></name><name><surname>Nelson</surname><given-names>JS</given-names></name><name><surname>Weinstein</surname><given-names>AS</given-names></name><name><surname>Fischbach</surname><given-names>AJ</given-names></name><name><surname>Chang</surname><given-names>CH</given-names></name><name><surname>Rotman</surname><given-names>M</given-names></name><name><surname>Asbell</surname><given-names>SO</given-names></name><name><surname>Krisch</surname><given-names>RE</given-names></name><etal/></person-group><article-title>Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials</article-title><source>J Natl Cancer Inst</source><year>1993</year><volume>85</volume><issue>9</issue><fpage>704</fpage><lpage>710</lpage><pub-id pub-id-type="doi">10.1093/jnci/85.9.704</pub-id><pub-id pub-id-type="pmid">8478956</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weller</surname><given-names>M</given-names></name><name><surname>Butowski</surname><given-names>N</given-names></name><name><surname>Tran</surname><given-names>DD</given-names></name><name><surname>Recht</surname><given-names>LD</given-names></name><name><surname>Lim</surname><given-names>M</given-names></name><name><surname>Hirte</surname><given-names>H</given-names></name><name><surname>Ashby</surname><given-names>L</given-names></name><name><surname>Mechtler</surname><given-names>L</given-names></name><name><surname>Goldlust</surname><given-names>SA</given-names></name><name><surname>Iwamoto</surname><given-names>F</given-names></name><etal/></person-group><article-title>Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial</article-title><source>Lancet Oncol</source><year>2017</year><volume>18</volume><fpage>1378</fpage><lpage>1385</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(17)30517-X</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Qian</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Yi</surname><given-names>Q</given-names></name></person-group><article-title>Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity</article-title><source>Clin Exp Immunol</source><year>2012</year><volume>170</volume><issue>2</issue><fpage>167</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2249.2012.04642.x</pub-id><pub-id pub-id-type="pmid">23039887</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grossman</surname><given-names>SA</given-names></name><name><surname>Ellsworth</surname><given-names>S</given-names></name><name><surname>Campian</surname><given-names>J</given-names></name><name><surname>Wild</surname><given-names>AT</given-names></name><name><surname>Herman</surname><given-names>JM</given-names></name><name><surname>Laheru</surname><given-names>D</given-names></name><name><surname>Brock</surname><given-names>M</given-names></name><name><surname>Balmanoukian</surname><given-names>A</given-names></name><name><surname>Ye</surname><given-names>X</given-names></name></person-group><article-title>Survival in patients with severe lymphopenia following treatment with radiation and chemotherapy for newly diagnosed solid tumors</article-title><source>J Natl Compr Canc Netw</source><year>2015</year><volume>13</volume><issue>10</issue><fpage>1225</fpage><lpage>1231</lpage><pub-id pub-id-type="doi">10.6004/jnccn.2015.0151</pub-id><pub-id pub-id-type="pmid">26483062</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stupp</surname><given-names>R</given-names></name><name><surname>Taillibert</surname><given-names>S</given-names></name><name><surname>Kanner</surname><given-names>A</given-names></name><name><surname>Read</surname><given-names>W</given-names></name><name><surname>Steinberg</surname><given-names>DM</given-names></name><name><surname>Lhermitte</surname><given-names>B</given-names></name><name><surname>Toms</surname><given-names>S</given-names></name><name><surname>Idbaih</surname><given-names>A</given-names></name><name><surname>Ahluwalia</surname><given-names>MS</given-names></name><name><surname>Fink</surname><given-names>K</given-names></name><etal/></person-group><article-title>Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial</article-title><source>JAMA</source><year>2017</year><volume>318</volume><issue>23</issue><fpage>2306</fpage><lpage>2316</lpage><pub-id pub-id-type="doi">10.1001/jama.2017.18718</pub-id><pub-id pub-id-type="pmid">29260225</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>HS</given-names></name><name><surname>Prados</surname><given-names>MD</given-names></name><name><surname>Wen</surname><given-names>PY</given-names></name><name><surname>Mikkelsen</surname><given-names>T</given-names></name><name><surname>Schiff</surname><given-names>D</given-names></name><name><surname>Abrey</surname><given-names>LE</given-names></name><name><surname>Yung</surname><given-names>WK</given-names></name><name><surname>Paleologos</surname><given-names>N</given-names></name><name><surname>Nicholas</surname><given-names>MK</given-names></name><name><surname>Jensen</surname><given-names>R</given-names></name><etal/></person-group><article-title>Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma</article-title><source>J Clin Oncol</source><year>2009</year><volume>27</volume><issue>28</issue><fpage>4733</fpage><lpage>4740</lpage><pub-id pub-id-type="doi">10.1200/JCO.2008.19.8721</pub-id><pub-id pub-id-type="pmid">19720927</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harris</surname><given-names>SJ</given-names></name><name><surname>Brown</surname><given-names>J</given-names></name><name><surname>Lopez</surname><given-names>J</given-names></name><name><surname>Yap</surname><given-names>TA</given-names></name></person-group><article-title>Immuno-oncology combinations: raising the tail of the survival curve</article-title><source>Cancer Biol Med</source><year>2016</year><volume>13</volume><issue>2</issue><fpage>171</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.20892/j.issn.2095-3941.2016.0015</pub-id><pub-id pub-id-type="pmid">27458526</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parsons</surname><given-names>DW</given-names></name><name><surname>Jones</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Lin</surname><given-names>JC</given-names></name><name><surname>Leary</surname><given-names>RJ</given-names></name><name><surname>Angenendt</surname><given-names>P</given-names></name><name><surname>Mankoo</surname><given-names>P</given-names></name><name><surname>Carter</surname><given-names>H</given-names></name><name><surname>Siu</surname><given-names>IM</given-names></name><name><surname>Gallia</surname><given-names>GL</given-names></name><etal/></person-group><article-title>An integrated genomic analysis of human glioblastoma multiforme</article-title><source>Science</source><year>2008</year><volume>321</volume><issue>5897</issue><fpage>1807</fpage><lpage>1812</lpage><pub-id pub-id-type="doi">10.1126/science.1164382</pub-id><pub-id pub-id-type="pmid">18772396</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bosch</surname><given-names>ML</given-names></name><name><surname>Prins</surname><given-names>RM</given-names></name></person-group><article-title>Prolonged survival for patients with recurrent glioblastoma multiforme who are treated with tumour lysate-pulsed autologous dendritic cells</article-title><source>Eur J Cancer</source><year>2015</year><volume>51</volume><issue>Supplement 1</issue><fpage>S6</fpage><lpage>S7</lpage></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larkin</surname><given-names>J</given-names></name><name><surname>Chmielowski</surname><given-names>B</given-names></name><name><surname>Lao</surname><given-names>CD</given-names></name><name><surname>Hodi</surname><given-names>FS</given-names></name><name><surname>Sharfman</surname><given-names>W</given-names></name><name><surname>Weber</surname><given-names>J</given-names></name><name><surname>Suijkerbuijk</surname><given-names>KPM</given-names></name><name><surname>Azevedo</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Reshef</surname><given-names>D</given-names></name><etal/></person-group><article-title>Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis</article-title><source>Oncologist</source><year>2017</year><volume>22</volume><issue>6</issue><fpage>709</fpage><lpage>718</lpage><pub-id pub-id-type="doi">10.1634/theoncologist.2016-0487</pub-id><pub-id pub-id-type="pmid">28495807</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maxwell</surname><given-names>R</given-names></name><name><surname>Jackson</surname><given-names>CM</given-names></name><name><surname>Lim</surname><given-names>M</given-names></name></person-group><article-title>Clinical trials investigating immune checkpoint blockade in glioblastoma</article-title><source>Curr Treat Options Oncol</source><year>2017</year><volume>18</volume><issue>8</issue><fpage>51</fpage><pub-id pub-id-type="doi">10.1007/s11864-017-0492-y</pub-id><pub-id pub-id-type="pmid">28785997</pub-id></element-citation></ref></ref-list></back></article>